NASDAQ:SCYX - SCYNEXIS Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.70 +0.05 (+3.03 %) (As of 04/23/2019 08:43 AM ET)Previous Close$1.65Today's Range$1.61 - $1.7352-Week Range$0.35 - $2.15Volume947,254 shsAverage Volume1.26 million shsMarket Capitalization$85.25 millionP/E RatioN/ADividend YieldN/ABeta2.38 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. The company also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC, to develop and commercialize rights for SCY-078. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey. Receive SCYX News and Ratings via Email Sign-up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SCYX Previous Symbol CUSIPN/A CIK1178253 Webwww.scynexis.com Phone201-884-5485Debt Debt-to-Equity Ratio0.48 Current Ratio8.76 Quick Ratio8.76Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$260,000.00 Price / Sales327.89 Cash FlowN/A Price / Cash FlowN/A Book Value$0.65 per share Price / Book2.62Profitability EPS (Most Recent Fiscal Year)($0.49) Net Income$-12,470,000.00 Net Margins-4,869.53% Return on Equity-74.32% Return on Assets-39.87%Miscellaneous Employees24 Outstanding Shares50,148,000Market Cap$85.25 million Next Earnings Date5/14/2019 (Estimated) OptionableOptionable SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions What is SCYNEXIS's stock symbol? SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX." How were SCYNEXIS's earnings last quarter? SCYNEXIS Inc (NASDAQ:SCYX) announced its quarterly earnings data on Tuesday, November, 13th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.18. The business earned $0.06 million during the quarter, compared to analyst estimates of $0.06 million. SCYNEXIS had a negative net margin of 4,869.53% and a negative return on equity of 74.32%. View SCYNEXIS's Earnings History. When is SCYNEXIS's next earnings date? SCYNEXIS is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for SCYNEXIS. What price target have analysts set for SCYX? 7 equities research analysts have issued 12 month price objectives for SCYNEXIS's stock. Their forecasts range from $4.00 to $9.00. On average, they anticipate SCYNEXIS's stock price to reach $5.50 in the next year. This suggests a possible upside of 223.5% from the stock's current price. View Analyst Price Targets for SCYNEXIS. What is the consensus analysts' recommendation for SCYNEXIS? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SCYNEXIS. What are Wall Street analysts saying about SCYNEXIS stock? Here are some recent quotes from research analysts about SCYNEXIS stock: 1. Maxim Group analysts commented, "Scynexis reported FY18 with operating expenses of $30.2M and a net loss of ($12.5M). The company ended the period with $44.2M in cash, excluding the sale of a portion of its business, and tax net operating losses (NOLs) in $6.7M, netting a pro forma cash balance of $51M in January. Scynexis also completed the sale of a $16.0M convertible note to March, which the company used to retire in full a previous term loan, strengthening its balance sheet further. Combined, Scynexis has runway at the current burn rate through key catalysts, including the NDA submission of ibrexafungerp for acute vulvovaginal candidiasis (VVC) in 2H20." (3/18/2019) 2. According to Zacks Investment Research, "SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina. " (3/12/2019) Has SCYNEXIS been receiving favorable news coverage? News coverage about SCYX stock has trended somewhat negative this week, InfoTrie reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. SCYNEXIS earned a media sentiment score of -1.6 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the near term. Who are some of SCYNEXIS's key competitors? Some companies that are related to SCYNEXIS include Savara (SVRA), XBiotech (XBIT), BioDelivery Sciences International (BDSI), Neptune Wellness Solutions (NEPT), AC Immune (ACIU), BIOFRONTERA AG/ADR (BFRA), Insys Therapeutics (INSY), PhaseBio Pharmaceuticals (PHAS), Karyopharm Therapeutics (KPTI), Kadmon (KDMN), MannKind (MNKD), Lannett (LCI), Constellation Pharmaceuticals (CNST), Immune Design (IMDZ) and Seres Therapeutics (MCRB). What other stocks do shareholders of SCYNEXIS own? Based on aggregate information from My MarketBeat watchlists, some companies that other SCYNEXIS investors own include Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Nabriva Therapeutics (NBRV), Micron Technology (MU), Trevena (TRVN), Verastem (VSTM), Ocular Therapeutix (OCUL), Viking Therapeutics (VKTX), Corbus Pharmaceuticals (CRBP) and Sorrento Therapeutics (SRNE). Who are SCYNEXIS's key executives? SCYNEXIS's management team includes the folowing people: Dr. Marco Taglietti, CEO, Pres & Director (Age 59)Mr. Eric Francois, Chief Financial Officer (Age 44)Mr. David Gonzalez Angulo, Chief Medical Officer (Age 54)Mr. Scott Sukenick J.D., Gen. Counsel (Age 41) How do I buy shares of SCYNEXIS? Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is SCYNEXIS's stock price today? One share of SCYX stock can currently be purchased for approximately $1.70. How big of a company is SCYNEXIS? SCYNEXIS has a market capitalization of $85.25 million and generates $260,000.00 in revenue each year. The company earns $-12,470,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. SCYNEXIS employs 24 workers across the globe. What is SCYNEXIS's official website? The official website for SCYNEXIS is http://www.scynexis.com. How can I contact SCYNEXIS? SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The company can be reached via phone at 201-884-5485 or via email at [email protected] MarketBeat Community Rating for SCYNEXIS (NASDAQ SCYX)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 357 (Vote Outperform)Underperform Votes: 194 (Vote Underperform)Total Votes: 551MarketBeat's community ratings are surveys of what our community members think about SCYNEXIS and other stocks. Vote "Outperform" if you believe SCYX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCYX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/23/2019 by MarketBeat.com StaffFeatured Article: What are the benefits of investing in REITs?